Unknown

Dataset Information

0

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.


ABSTRACT: Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of Childhood Cancer study (ABLE/PBMTC1202, NCT02067832) evaluated the immune profiles in chronic GVHD (cGVHD) and late acute GVHD (L-aGVHD). Peripheral blood immune cell and plasma markers were analyzed at day 100 post-HSCT and correlated with GVHD diagnosed according to the National Institutes of Health consensus criteria (NIH-CC) for cGVHD. Of 302 children enrolled, 241 were evaluable as L-aGVHD, cGVHD, active L-aGVHD or cGVHD, and no cGVHD/L-aGVHD. Significant marker differences, adjusted for major clinical factors, were defined as meeting all 3 criteria: receiver-operating characteristic area under the curve ≥0.60, P ≤ .05, and effect ratio ≥1.3 or ≤0.75. Patients with only distinctive features but determined as cGVHD by the adjudication committee (non-NIH-CC) had immune profiles similar to NIH-CC. Both cGVHD and L-aGVHD had decreased transitional B cells and increased cytolytic natural killer (NK) cells. cGVHD had additional abnormalities, with increased activated T cells, naive helper T (Th) and cytotoxic T cells, loss of CD56bright regulatory NK cells, and increased ST2 and soluble CD13. Active L-aGVHD before day 114 had additional abnormalities in naive Th, naive regulatory T (Treg) cell populations, and cytokines, and active cGVHD had an increase in PD-1- and a decrease in PD-1+ memory Treg cells. Unsupervised analysis appeared to show a progression of immune abnormalities from no cGVHD/L-aGVHD to L-aGVHD, with the most complex pattern in cGVHD. Comprehensive immune profiling will allow us to better understand how to minimize L-aGVHD and cGVHD. Further confirmation in adult and pediatric cohorts is needed.

SUBMITTER: Schultz KR 

PROVIDER: S-EPMC7146024 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.

Schultz Kirk R KR   Kariminia Amina A   Ng Bernard B   Abdossamadi Sayeh S   Lauener Madeline M   Nemecek Eneida R ER   Wahlstrom Justin T JT   Kitko Carrie L CL   Lewis Victor A VA   Schechter Tal T   Jacobsohn David A DA   Harris Andrew C AC   Pulsipher Michael A MA   Bittencourt Henrique H   Choi Sung Won SW   Caywood Emi H EH   Kasow Kimberly A KA   Bhatia Monica M   Oshrine Benjamin R BR   Flower Allyson A   Chaudhury Sonali S   Coulter Donald D   Chewning Joseph H JH   Joyce Michael M   Savasan Sureyya S   Pawlowska Anna B AB   Megason Gail C GC   Mitchell David D   Cheerva Alexandra C AC   Lawitschka Anita A   Azadpour Shima S   Ostroumov Elena E   Subrt Peter P   Halevy Anat A   Mostafavi Sara S   Cuvelier Geoffrey D E GDE  

Blood 20200401 15


Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of Childhood Cancer study (ABLE/PBMTC1202, NCT02067832) evaluated the immune profiles in chronic GVHD (cGVHD) and late acute GVHD (L-aGVHD). Peripheral blood immune cell and plasma markers were analyzed at day 100 post-HSCT and correlated with GVHD diagnosed according to the National Institutes of Health consensus criteria (NIH-CC)  ...[more]

Similar Datasets

| S-EPMC2713471 | biostudies-other
| S-EPMC3971477 | biostudies-literature
| S-EPMC8260916 | biostudies-literature
| S-EPMC6911839 | biostudies-literature
| S-EPMC10365934 | biostudies-literature
| S-EPMC4982453 | biostudies-other
| S-EPMC10365946 | biostudies-literature
| S-EPMC10440469 | biostudies-literature
| S-EPMC10011883 | biostudies-literature
| S-EPMC10505719 | biostudies-literature